THE SHORT ANSWER
High-Performance Science Teams™ helps sponsor-side clinical study teams clinical operations, medical, data management, biostatistics, regulatory, and CRO partners make faster, cleaner decisions. It targets the team behaviors behind avoidable protocol amendments, slow escalations, and sponsor CRO friction, the delays a study team can actually control.
What does a day of clinical trial delay really cost?
Tufts Center for the Study of Drug Development estimates the mean direct cost of running a Phase II or Phase III trial at roughly $40,000 per day, about $23,700 per day for Phase II and $55,700 for Phase III (Tufts CSDD, 2024). That is before counting the commercial value of a later approval.
Protocol amendments are one of the most visible sources of that delay. In Tufts CSDD’s 2016 benchmark, 57% of protocols had at least one substantial amendment, nearly half of those amendments were judged avoidable, and the median direct cost to implement one was $141,000 in Phase II and $535,000 in Phase III. Tufts’ more recent benchmarking found that most amendments are now judged unavoidable driven by regulatory requests and changes in study strategy, but that still leaves a costly avoidable share, and strategy changes are often a symptom of misalignment upstream.
Which clinical trial delays are team problems, not science problems?
Enrollment curves and regulatory feedback get the blame. But inside most study execution teams, a set of controllable behaviors quietly adds weeks:
- Protocols designed without operational voice. Clinical science finalizes the protocol before clinical operations, data management, and sites weigh in on feasibility, then amends it after first patient in.
- Decisions escalated instead of made. The study team treats governance committees as the default decision-maker, so routine calls on eligibility clarifications or vendor issues wait for the next meeting cycle.
- Medical vs. operations tension. Medical monitors and clinical operations optimize for different risks and rarely resolve the trade-off explicitly.
- The sponsor–CRO blame loop. Vendor oversight becomes policing. The CRO learns to report green until it’s red, and the sponsor learns to distrust the dashboard.
- Status meetings instead of decision meetings. Study team meetings recite enrollment numbers and open queries without assigning owners to the enrollment rescue plan or the database-lock critical path.
Why don’t better CTMS dashboards or another CRO fix it?
Life science companies reach for vertical fixes when a trial slips: a new CTMS or RBQM platform, a reorganized clinical operations function, a CRO switch. The dashboard shows the delay more clearly. It does not change how the study team decides what to do about it.
Switching CROs is the most expensive version of the same mistake. If the sponsor-side team’s decision rights, escalation norms, and accountability are unclear, the new partner inherits the same dynamics — along with a transition that costs months.
How does High-Performance Science Teams™ work for clinical study teams?
The program applies Guttman Development Strategies’ horizontal high-performance team model to the study execution team, working on live studies rather than simulations. Where it helps, the engagement can be designed to include CRO counterparts so the partnership operates as one team.
| Delay pattern | Root behavior | What HPT installs |
| Avoidable protocol amendments | Feasibility input arrives after protocol finalization | Cross-functional protocol-design protocol: clinical ops, data management, biostatistics, and site input before sign-off |
| Slow escalations | Unclear decision rights at study-team level | A decision charter defining what the study team decides, what it escalates, and within what time frame |
| Medical vs. operations standoffs | Trade-offs left implicit | Explicit conflict protocol that frames disagreements as study-risk decisions |
| Sponsor–CRO mistrust | Oversight as policing | Joint team agreements on early bad-news reporting and shared accountability for milestones |
| Missed database lock | No single owner of the critical path | Peer accountability for FPI, LPI, and database-lock milestones across functions |
What is outside the scope of the program?
High-Performance Science Teams™ does not replace patient-recruitment strategy, site-selection analytics, or protocol-design expertise. It makes the team that uses those inputs faster and more aligned, and it works alongside the specialist partners you already rely on.
Who is it for?
VPs of Clinical Operations, Heads of Clinical Development, CMOs, study and program leads, and alliance managers at biotech and pharma sponsors running Phase I–III programs, especially teams managing one or more CRO partnerships.
How do we get started?
Start with the Science Team 360™, a short, confidential team-level diagnostic that shows exactly where decision rights, alignment, and accountability are breaking down inside your clinical study team. You get a readout before anyone commits to a full engagement.
Request a Science Team 360™ conversation at bench2business.bio.
Frequently asked questions
What causes clinical trial delays that a study team can control?
Controllable delays usually come from team behavior: protocols finalized without operational and site input, decisions escalated instead of made at study-team level, unresolved medical-versus-operations trade-offs, and sponsor CRO relationships where bad news travels late.
How much does a day of clinical trial delay cost?
Tufts CSDD estimates the mean direct cost at roughly $40,000 per day for Phase II and III trials — about $23,700 for Phase II and $55,700 for Phase III — excluding lost commercial value.
How does High-Performance Science Teams™ improve sponsor–CRO collaboration?
It creates joint agreements on decision rights, early reporting of risk, and shared milestone accountability, so the sponsor and CRO operate as one study team instead of a buyer and a vendor.
Does this replace risk-based quality management or CTMS tools?
No. RBQM and CTMS surface risks and status. High-Performance Science Teams™ improves how the study team acts on that information.
How do we start?
With the Science Team 360™, a confidential team diagnostic that pinpoints where decision rights, alignment, and accountability break down before any larger engagement.
Sources
- Tufts CSDD, “How Much Does a Day of Delay in a Clinical Trial Really Cost?” White paper, August 2024 — https://csdd.tufts.edu/publications/articles
- Getz K.A. et al. “The Impact of Protocol Amendments on Clinical Trial Performance and Cost.” Therapeutic Innovation & Regulatory Science, 2016 — https://pubmed.ncbi.nlm.nih.gov/30227022/
- Tufts CSDD, “New Benchmarks on Protocol Amendment Practices, Trends and their Impact on Clinical Trial Performance” (preprint) — https://www.researchsquare.com/article/rs-3168679/v1
- Guttman, H.M. Great Business Teams: Cracking the Code for Standout Performance (Wiley, 2008) — https://www.guttmandev.com/great-business-teams
Figures from third-party studies are cited as published. Cross-industry data is presented as directional for life science. Program outcomes described are targets teams track against their own Science Team 360™ baseline, not guaranteed results.